ERBB2 and breast cancer: However, the incidence of HER2-positive breast cancer (RESMIN: n = 26, 53.1 % vs. non-RESMIN: n = 39, 41.1%; p = 0.041) and TNBC (RESMIN: n = 5, 10.2 % vs. non-RESMIN: n = 9, 9.5 %; p = 0.007) was significantly higher in the RESMIN group than in the non-RESMIN group (Table 1).